6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both Plus Mealtime Insulin in Patients With Type 2 Diabetes Mellitus With a 6-month Safety Extension Period
收藏DataCite Commons2025-05-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00007683/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
Primary Objective:
- To compare the efficacy of insulin glargine new formulation and Lantus in terms of
change in HbA1c from baseline to endpoint (scheduled month 6) in adult participants with
type 2 diabetes mellitus
Secondary Objectives:
- To compare the efficacy of insulin glargine new formulation and Lantus in terms of
occurrence of nocturnal Hypoglycemia
提供机构：
Vivli
创建时间：
2022-02-10
